MS treatment: Clinical trials due as human stem cells research shows promise
In fact, the process appeared more rapid and efficient than with other cell sources
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The first clinical trials of a revolutionary approach to treating multiple sclerosis with stem cells derived from the patient’s own skin could begin soon following research showing that it works well on laboratory mice, scientists said.
A study has for the first time found that human skin cells converted into stem cells can be used to treat laboratory mice with a condition similar to multiple-sclerosis, where the fatty covering surrounding the nerves is lost.
Scientists in the US said initial clinical trials on human patients using a similar approach could begin in 2015, with full-scale studies soon after. The skin cells were first genetically engineered to become induced pluripotent stem cells (iPS) before being converted to the specialised cells that make the fatty myelin sheaths, which insulate nerve cells in a similar way to the plastic covering of an electrical wire. The myelin is gradually degraded in MS patients.
Scientists were able to turn the iPS cells into oligodendrocyte progenitor cells which were injected into the mice. These progenitor cells went on to become fully specialised oligodendrocytes, the cells responsible for making the myelin sheath.
“The new population of oligodendrocyte progenitor cells and oligodendrocytes was dense, abundant and complete. In fact, they re-myelination process appeared more rapid and efficient than with other cell sources,” said neurologist Steven Goldman of Rochester University Medical Centre in New York. Induced pluripotent stem cells are created by adding several genes to ordinary skin cells. This has the effect of “reprogramming” them back to an earlier, embryonic-like state, but has the ethical advantage over true embyronic stem cells in that they do not require the creation of human embryos.
Clinical trials of human induced pluripotent stem cells on MS patients are being funded by an organisation called New York State Stem Cell Science, which has already approved initial trials using stem cells, which are due to begin within two years.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments